Literature DB >> 20605950

Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain.

Yael Wexler-Cohen1, Avraham Ashkenazi, Mathias Viard, Robert Blumenthal, Yechiel Shai.   

Abstract

The interactions between the N- and C-terminal heptad repeat (NHR and CHR) regions of the human immunodeficiency virus (HIV-1) glycoprotein gp41 create a structure comprising a 6-helix bundle (SHB). A sequence in the SHB named the "pocket" is crucial for the SHB's stability and for the fusion inhibitory activity of 36-residue NHR peptide N36. We report that a short 27-residue peptide, N27, which lacks the pocket sequence, exhibits potent inhibitory activity in both cell-cell and virus-cell fusion assays when fatty acids were conjugated to its N but not C terminus. Furthermore, mutations in the positions that prevent interaction with the CHR but not with the NHR resulted in a dramatic reduction in N27 activity. These data support a mechanism in which N27 mainly targets the CHR rather than the internal NHR coiled-coil, reveal the N-terminal edge of the endogenous core structure in situ and hence complement our recent findings of the C-terminal edge of the core, and provide a new approach for designing short inhibitors from the NHR region of other lentiviruses due to similarities in their envelope proteins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20605950      PMCID: PMC2974423          DOI: 10.1096/fj.09-151704

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  37 in total

1.  Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.

Authors:  Elisabetta Bianchi; Marco Finotto; Paolo Ingallinella; Renee Hrin; Anthony V Carella; Xiaoli S Hou; William A Schleif; Michael D Miller; Romas Geleziunas; Antonello Pessi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-29       Impact factor: 11.205

Review 2.  HIV entry and its inhibition.

Authors:  D C Chan; P S Kim
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

Review 3.  Coiled coils in both intracellular vesicle and viral membrane fusion.

Authors:  J J Skehel; D C Wiley
Journal:  Cell       Date:  1998-12-23       Impact factor: 41.582

4.  Atomic structure of the ectodomain from HIV-1 gp41.

Authors:  W Weissenhorn; A Dessen; S C Harrison; J J Skehel; D C Wiley
Journal:  Nature       Date:  1997-05-22       Impact factor: 49.962

5.  Molecular determinants of acute single-cell lysis by human immunodeficiency virus type 1.

Authors:  J Cao; I W Park; A Cooper; J Sodroski
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

6.  The fusion activity of HIV-1 gp41 depends on interhelical interactions.

Authors:  Tara R Suntoke; David C Chan
Journal:  J Biol Chem       Date:  2005-03-16       Impact factor: 5.157

7.  HIV-1-infected blood mononuclear cells form an integrin- and agrin-dependent viral synapse to induce efficient HIV-1 transcytosis across epithelial cell monolayer.

Authors:  Annette Alfsen; Huifeng Yu; Aude Magérus-Chatinet; Alain Schmitt; Morgane Bomsel
Journal:  Mol Biol Cell       Date:  2005-06-22       Impact factor: 4.138

8.  Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.

Authors:  Shuwen Liu; Hong Lu; Jinkui Niu; Yujia Xu; Shuguang Wu; Shibo Jiang
Journal:  J Biol Chem       Date:  2005-01-07       Impact factor: 5.157

9.  Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.

Authors:  Gregory B Melikyan; Marc Egelhofer; Dorothee von Laer
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

10.  Interaction of the HIV-1 fusion peptide with phospholipid vesicles: different structural requirements for fusion and leakage.

Authors:  J L Nieva; S Nir; A Muga; F M Goñi; J Wilschut
Journal:  Biochemistry       Date:  1994-03-22       Impact factor: 3.162

View more
  17 in total

Review 1.  Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.

Authors:  Lifeng Cai; Miriam Gochin; Keliang Liu
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

2.  Swapped-domain constructs of the glycoprotein-41 ectodomain are potent inhibitors of HIV infection.

Authors:  Shidong Chu; Hardeep Kaur; Ariana Nemati; Joseph D Walsh; Vivian Partida; Shao-Qing Zhang; Miriam Gochin
Journal:  ACS Chem Biol       Date:  2015-02-17       Impact factor: 5.100

3.  A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.

Authors:  Xiaoran Tang; Hongliang Jin; Yue Chen; Li Li; Yuanmei Zhu; Huihui Chong; Yuxian He
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

Review 4.  Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy.

Authors:  Himanshu Garg; Mathias Viard; Amy Jacobs; Robert Blumenthal
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

5.  Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.

Authors:  Xiaohui Ding; Xiujuan Zhang; Huihui Chong; Yuanmei Zhu; Huamian Wei; Xiyuan Wu; Jinsheng He; Xinquan Wang; Yuxian He
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

Review 6.  Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides.

Authors:  Avraham Ashkenazi; Yechiel Shai
Journal:  Eur Biophys J       Date:  2011-01-22       Impact factor: 1.733

7.  Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry.

Authors:  J Nicholas Francis; Joseph S Redman; Debra M Eckert; Michael S Kay
Journal:  Bioconjug Chem       Date:  2012-05-17       Impact factor: 4.774

8.  A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity.

Authors:  Huihui Chong; Jing Xue; Shengwen Xiong; Zhe Cong; Xiaohui Ding; Yuanmei Zhu; Zixuan Liu; Ting Chen; Yifan Feng; Lei He; Yan Guo; Qiang Wei; Yusen Zhou; Chuan Qin; Yuxian He
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

9.  Structural and functional properties of the membranotropic HIV-1 glycoprotein gp41 loop region are modulated by its intrinsic hydrophobic core.

Authors:  Jiayin Qiu; Avraham Ashkenazi; Shuwen Liu; Yechiel Shai
Journal:  J Biol Chem       Date:  2013-08-19       Impact factor: 5.157

Review 10.  Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

Authors:  Christopher J De Feo; Carol D Weiss
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.